You are here

larotrectinib

Follow-Up Data on Bayer’s Larotrectinib Hints at Potentially Curative Impact

BioSpace

Thu, 07/7/22 - 10:29 am

Shattering an old record, FDA quickly OKs pioneering, site-agnostic cancer drug larotrectinib from Loxo and Bayer

Endpoints

Mon, 11/26/18 - 05:53 pm

personalized medicine

Loxo's targeted therapy holds up to Roche challenge

Biopharma Dive

Sun, 10/21/18 - 11:36 pm

3 Biotechs Awaiting FDA Approval Decisions

Motley Fool

Tue, 10/16/18 - 11:52 am

FDA starts speedy review of Loxo’s site-agnostic cancer drug larotrectinib

Fierce Biotech

Tue, 05/29/18 - 11:41 am

metastatic solid tumors

[video]Is Loxo Oncology's Deal With Bayer Bad News?

Motley Fool

Sat, 11/18/17 - 04:23 pm

Loxo Oncology's Up 230% in the Past Year -- Can You Still Make Money Buying It?

Motley Fool

Sun, 09/17/17 - 09:53 am

Loxo Oncology Shares Rally, Despite Diluting Investors

Motley Fool

Thu, 06/15/17 - 09:41 am

A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us

Forbes

Sun, 06/4/17 - 11:40 am

clinical trials

Loxo takes center stage at ASCO with its groundbreaking shot at a biomarker-based cancer drug approval

Endpoints

Sat, 06/3/17 - 09:21 am